Re-listened to the Q3 conference callIt is always good to re-listen to these calls because I find you always pick up on things you did not hear the first time around.
What I did hear the first time around was a lot of enthusiatic comments about TH-1902. But upon listening again, it was even more striking. We know they are much more aware of things that are going on in the phase 1a trial than they are currently letting us know about, but it is apparent those things are leading them to characterize their hopes for this trial in a very, very positive way. So that is encouraging.
On the issue of the neutropenia and reaching the MTD, Christian indicated no surprise at all about the neutropenia at this level of dosage and said they know they are already close to DLT's. He made a comment that basically said they know some Docetaxel will get into healthy cells but beleive more will get into the cancerous cells. So, while we did not get a description of exactly how Docetaxel is getting into healthy cells they clearly expect it to at some point. That may be something for Qwerty to give some thought to. If you want to listen to it, it came at the 40:25 mark of the call. BUt what I heard was they totally expect neutropenia at some point to occur and it probably will occur sometime around where they are at now in the trial.